Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns—NHANES 2007–2012

Abstract

ObjectiveTo describe the estimated prevalence and temporal trends of chronic kidney disease (CKD) treatment patterns, and the association between CKD and potential factors for type 2 diabetes mellitus (T2DM) in different demographic subgroups.Research design and methodsThis was a cross-sectional analysis of adults with T2DM based on multiple US National Health and Nutrition Examination Survey (NHANES) datasets developed during 2007–2012. CKD severity was defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 guidelines using the CKD Epidemiology Collaboration (CKD-EPI) equation: mild to moderate=stages 1–3a; moderate to kidney failure=stages 3b–5. Multivariable logistic regression analyses were performed to assess the associations between CKD and potential factors.ResultsOf the adult individuals with T2DM (n=2006), age-adjusted CKD prevalence was 38.3% during 2007–2012; 77.5% were mild-to-moderate CKD. The overall age-adjusted prevalence of CKD was 40.2% in 2007–2008, 36.9% in 2009–2010, and 37.6% in 2011–2012. The prevalence of CKD in T2DM was 58.7% in patients aged ≥65 years, 25.7% in patients aged <65 years, 43.5% in African-Americans and Mexican-Americans, and 38.7% in non-Hispanic whites. The use of antidiabetes and antihypertensive medications generally followed treatment guideline recommendations. Older age, higher hemoglobin A1c (HbA1c), systolic blood pressure (SBP), and having hypertension were significantly associated with CKD presence but not increasing severity of CKD.ConclusionsCKD continued to be prevalent in the T2DM population; prevalence remained fairly consistent over time, suggesting that current efforts to prevent CKD could be improved overall, especially by monitoring certain populations more closely.

The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus

“…Renal impairment is a common comorbidity in patients with T2DM . It is therefore important to investigate if the PK of investigational therapeutic agents is altered among subjects with renal impairment.…”

“…Type 2 diabetes mellitus (T2DM) is the leading cause of end‐stage renal disease and carries a significant cost burden, totaling US$20 000 to US$40 000 per person per year . A cross‐sectional analysis of multiple United States National Health and Nutrition Examination Survey data from 2007 to 2012 reported an age‐adjusted chronic kidney disease prevalence of 38.3% in adults with T2DM …”

A demographic, clinical, and behavioral typology of obesity in the United States: an analysis of National Health and Nutrition Examination Survey 2011–2012

“…Prevalence of chronic conditions examined included asthma, arthritis, congestive heart failure, coronary heart disease, angina, heart attack, stroke, emphysema, cancer, pain score, anxiety score, diabetes, HTN, dyslipidemia, sleep disorder and depression score. Most chronic conditions were identified through self-report of previous diagnosis by a health care provider, except for dyslipidemia, HTN and diabetes, which were defined as either self-reported diagnosis or currently taking medication (15, 16). Well-being measures included anxiety, depression and pain.…”

Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials

“…Current estimates project that the global prevalence of diabetes will exceed 550 million people by the year 2035 . Approximately 75% of patients with newly diagnosed ESRD have diabetes with hypertension . Additionally, the prevalence of reduced eGFR increased from 9.2% (95% CI, 6.2%‐12.2%) from 1988 to 1994 to 14.1% (95% CI, 11.3%‐17.0%) from 2009 to 2014, with an alarming increased RR of 61% (adjusted prevalence ratio, 1.61 [95% CI], 1.33‐1.95).…”